Harfst & Associates’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,442
| Closed | -$219K | – | 110 |
|
|
2025
Q1 | $219K | Sell |
2,442
-448
| -16% | -$40.1K | 0.05% | 113 |
|
|
2024
Q4 | $231K | Sell |
2,890
-1,913
| -40% | -$166K | 0.05% | 87 |
|
|
2024
Q3 | $432K | Sell |
4,803
-2,558
| -35% | -$215K | 0.1% | 77 |
|
|
2024
Q2 | $579K | Sell |
7,361
-643
| -8% | -$52.7K | 0.14% | 73 |
|
|
2024
Q1 | $698K | Sell |
8,004
-14,757
| -65% | -$1.26M | 0.17% | 73 |
|
|
2023
Q4 | $1.88M | Sell |
22,761
-668
| -3% | -$50.9K | 0.5% | 48 |
|
|
2023
Q3 | $1.84M | Sell |
23,429
-14
| -0.1% | -$1.17K | 0.52% | 45 |
|
|
2023
Q2 | $2.07M | Buy |
23,443
+8,138
| +53% | +$701K | 0.55% | 46 |
|
|
2023
Q1 | $1.23M | Buy |
15,305
+84
| +0.6% | +$6.85K | 0.35% | 61 |
|
|
2022
Q4 | $1.18M | Buy |
15,221
+315
| +2% | +$25.5K | 0.34% | 59 |
|
|
2022
Q3 | $1.2M | Buy |
14,906
+1,384
| +10% | +$124K | 0.36% | 57 |
|
|
2022
Q2 | $1.21M | Sell |
13,522
-1,628
| -11% | -$165K | 0.34% | 59 |
|
|
2022
Q1 | $1.68M | Buy |
15,150
+2,397
| +19% | +$253K | 0.39% | 48 |
|
|
2021
Q4 | $1.32M | Buy |
12,753
+2,317
| +22% | +$268K | 0.34% | 57 |
|
|
2021
Q3 | $1.31M | Buy |
10,436
+109
| +1% | +$14.1K | 0.36% | 49 |
|
|
2021
Q2 | $1.28M | Sell |
10,327
-90
| -0.9% | -$11.3K | 0.37% | 52 |
|
|
2021
Q1 | $1.23M | Buy |
10,417
+1,317
| +14% | +$154K | 0.37% | 53 |
|
|
2020
Q4 | $1.06M | Buy |
9,100
+1,291
| +17% | +$142K | 0.39% | 47 |
|
|
2020
Q3 | $811K | Sell |
7,809
-294
| -4% | -$29.5K | 0.34% | 46 |
|
|
2020
Q2 | $743K | Sell |
8,103
-101
| -1% | -$9.69K | 0.32% | 45 |
|
|
2020
Q1 | $739K | Buy |
8,204
+390
| +5% | +$41.5K | 0.38% | 36 |
|
|
2019
Q4 | $886K | Buy |
7,814
+238
| +3% | +$26.1K | 0.34% | 40 |
|
|
2019
Q3 | $822K | Buy |
7,576
+26
| +0.3% | +$2.71K | 0.34% | 38 |
|
|
2019
Q2 | $735K | Buy |
7,550
+504
| +7% | +$46K | 0.3% | 38 |
|
|
2019
Q1 | $641K | Buy |
7,046
+1,014
| +17% | +$90.8K | 0.27% | 41 |
|
|
2018
Q4 | $548K | Buy |
6,032
+468
| +8% | +$43.7K | 0.26% | 35 |
|
|
2018
Q3 | $547K | Buy |
5,564
+214
| +4% | +$19.8K | 0.23% | 37 |
|
|
2018
Q2 | $458K | Buy |
5,350
+97
| +2% | +$8.1K | 0.19% | 43 |
|
|
2018
Q1 | $421K | Buy |
5,253
+416
| +9% | +$34.3K | 0.17% | 52 |
|
|
2017
Q4 | $390K | Buy |
4,837
+137
| +3% | +$11K | 0.16% | 54 |
|
|
2017
Q3 | $365K | Buy |
4,700
+25
| +0.5% | +$2.08K | 0.15% | 55 |
|
|
2017
Q2 | $414K | Buy |
4,675
+1,162
| +33% | +$98K | 0.17% | 42 |
|
|
2017
Q1 | $283K | Sell |
3,513
-724
| -17% | -$56.6K | 0.12% | 51 |
|
|
2016
Q4 | $301K | Buy |
4,237
+1,318
| +45% | +$104K | 0.15% | 50 |
|
|
2016
Q3 | $252K | Sell |
2,919
-24,738
| -89% | -$2.16M | 0.13% | 60 |
|
|
2016
Q2 | $2.4M | Buy |
27,657
+22,350
| +421% | +$1.81M | 0.97% | 16 |
|
|
2016
Q1 | $398K | Sell |
5,307
-24,870
| -82% | -$1.87M | 0.26% | 35 |
|
|
2015
Q4 | $2.32M | Buy |
30,177
+284
| +1% | +$21.4K | 0.95% | 16 |
|
|
2015
Q3 | $2M | Buy |
29,893
+25,030
| +515% | +$1.84M | 0.88% | 19 |
|
|
2015
Q2 | $360K | Buy |
+4,863
| New | +$372K | 0.2% | 28 |
|
Other funds holding MDT
Harfst & Associates's MDT Position: Q2 2025 in Review
Harfst & Associates sold out of Medtronic (MDT) in Q2 2025, closing a stake of 2,442 shares — an estimated $219K sold.
Harfst & Associates first reported a position in MDT in Q2 2015 and held it in 40 quarters. The position peaked at $2.4M in Q2 2016. 2,140 funds tracked by Wall St. Rank hold MDT as of Q2 2025.
- Harfst & Associates reported no remaining Medtronic position as of Q2 2025 after selling out during the quarter.
- Harfst & Associates sold 2,442 Medtronic shares in Q2 2025, an estimated $219K.
- Harfst & Associates first reported a position in Medtronic in Q2 2015 and held it in 40 quarters.
- Harfst & Associates's Medtronic position peaked at $2.4M in Q2 2016.
- 2,140 funds tracked by Wall St. Rank held Medtronic as of Q2 2025.
Based on Harfst & Associates's 13F filing for Q2 2025, filed 13 Aug 2025.